Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients by Straver, Marieke E. et al.
ORIGINAL ARTICLE
Feasibility of FDG PET/CT to monitor the response
of axillary lymph node metastases to neoadjuvant
chemotherapy in breast cancer patients
Marieke E. Straver & Tjeerd S. Aukema & Renato A. Valdes Olmos &
Emiel J. T. Rutgers & Kenneth G. A. Gilhuijs & Margaret E. Schot & Wouter V. Vogel &
Marie-Jeanne T. F. D. Vrancken Peeters
Received: 1 October 2009 /Accepted: 17 November 2009 /Published online: 4 February 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose The aim of this study was to assess the accuracy
of
18F-fluorodeoxyglucose (FDG) positron emission to-
mography (PET)/CT to visualize lymph node metastases
before the start of neoadjuvant chemotherapy and to
determine how often the visualization is sufficiently
prominent to allow monitoring of the axillary response.
Methods Thirty-eight patients with invasive breast cancer of
>3 cm and/or lymph node metastasis underwent FDG PET/
CT before neoadjuvant chemotherapy. The results of the FDG
PET/CT were compared with those from ultrasonography
with fine-needle aspiration (FNA) cytology or sentinel node
biopsy. Patients suitable for response monitoring of the axilla
weredefinedashavingeitheramaximumstandardizeduptake
value (SUVmax)≥2.5 or a tumour to background ratio ≥5i n
the most intense lymph node.
Results The sensitivity and specificity of FDG PET/CT in
detectingaxillaryinvolvementwere97and100%,respectively.
No difference existed between the SUVmax of the primary
tumour and that from the related most intense lymph node
metastasis. Moreover, the mean tumour to background ratio
was 90% higher in the lymph nodes compared to the primary
tumour (p=0.006). Ninety-three per cent of the patients had
sufficient uptake in the lymph nodes to qualify for subsequent
response monitoring of the axilla. A considerable distinction
in metabolic activity was observed between the different
subtypes of breast cancer. The mean SUVmax in lymph node
metastases of oestrogen receptor (ER)-positive, triple-negative
and human epidermal growth factor receptor 2 (HER2)-
positive tumours was 6.6, 11.6 and 6.6, respectively.
Conclusion The high accuracy in visualizing lymph node
metastases and the sufficiently high SUVmax and tumour to
background ratio at baseline suggest that it is feasible to
monitor the axillary response with FDG PET/CT, especially
in triple-negative tumours.
Keywords Breastcancer.Axillarylymphnodemetastasis.
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Introduction
The use of neoadjuvant chemotherapy plays an important role
in the treatment of breast cancer. One of the major advantages
of neoadjuvant chemotherapy is downstaging of the tumour
load. As a result, inoperable advanced tumours may become
operable and patients with large operable tumours may be
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DOI 10.1007/s00259-009-1343-2offered breast-conserving surgery (BCS) [1, 2]. Another
advantage of neoadjuvant chemotherapy is the possibility
to monitor the response of the primary tumour to chemo-
therapy. Interim evaluation during neoadjuvant chemo-
therapy creates the opportunity to switch to another regimen
in the case of unfavourable response [3]. Furthermore,
response monitoring enables and moderates translational
research which provides more insight into the behaviour of
different tumour subtypes and predictive factors [4, 5].
Response monitoring is crucial in the neoadjuvant
setting, as it defines the criteria to switch the chemotherapy
regimen or to perform early surgery in insufficiently
responding tumours at an early time point. After the
administration of chemotherapy, response monitoring ena-
bles the evaluation of the extent of the residual tumour to
select patients for breast-conserving therapy.
The axillary response after neoadjuvant chemotherapy
yields prognostic information. Rouzier et al. showed that
after neoadjuvant chemotherapy a complete remission of
nodal metastases was a strong predictor of disease-free
survival (48.7 versus 73.5% after 5 years) [6]. Early
knowledge of the response of axillary lymph node
metastases may therefore be helpful to tailor the systemic
treatment to individual response. Furthermore, a reliable
method to evaluate the axillary tumour response is essential
in order to reduce the rate of unnecessary axillary lymph
node dissections (ALND), without compromising oncolog-
ical safety. Patients who achieve a complete remission of
their lymph node metastasis could potentially be treated
with radiation therapy only. Unfortunately, to date it is
not possible to reliably identify these patients. Physical
examination and conventional imaging techniques, like
MRI and ultrasound, do not have the ability to evaluate
the response of axillary lymph node metastasis [7].
Furthermore, the accuracy of the sentinel node procedure
after neoadjuvant chemotherapy in patients with proven
lymph node metastases remains questionable [8]. At
present, the most accurate assessment of the axillary
tumour response is an ALND and therefore ‘axilla-
conserving therapy’ is not yet among the benefits of
neoadjuvant chemotherapy.
Some evidence exists that positron emission tomography
(PET)/CT using
18F-fluorodeoxyglucose (FDG) may suc-
cessfully monitor the response of the primary tumour to
neoadjuvant chemotherapy [9–17]. The potential value of
FDG PET to assess the response of axillary lymph node
metastases to neoadjuvant chemotherapy is, however,
currently unknown. The primary aim of this study was to
assess the accuracy of FDG PET/CT to visualize lymph
node metastases before the start of neoadjuvant chemother-
apy. The second aim was to determine how often the
visualization is sufficiently prominent to allow monitoring
of the axillary response with FDG PET/CT.
Materials and methods
Patients
Women who presented with invasive breast cancer larger
than 3 cm in diameter and/or at least one tumour-positive
axillary lymph node were scheduled to be treated with
neoadjuvant chemotherapy in our institute. Since Septem-
ber 2007 patients were asked to participate in a pilot study
to assess the value of FDG PET/CT in the neoadjuvant
setting. This study was approved by the Institutional Ethics
Committee and informed consent was obtained from all
patients.
We analysed 38 patients who had an FDG PET/CT scan
before the administration of neoadjuvant chemotherapy. All
breast cancers were initially diagnosed by fine-needle
aspiration (FNA). Core biopsy was used to determine
hormone receptors and human epidermal growth factor
receptor 2 (HER2) status and to obtain tumour tissue for
expression microarray analysis [5]. The tumour size was
assessed with ultrasound, mammography and MRI. Axil-
lary staging was primarily done with ultrasonography and
FNA of suspect lymph nodes. In patients with negative
lymph nodes (ultrasound and/or FNA cytology negative) a
sentinel node biopsy (SNB) procedure was performed prior
to neoadjuvant chemotherapy. To assess the presence of
distant metastases liver ultrasound, bone scintigraphy and
chest X-ray were performed in all patients. Neoadjuvant
chemotherapy was followed by BCS or mastectomy. All
patients with proven axillary lymph node metastases prior
to neoadjuvant chemotherapy underwent an ALND after
neoadjuvant chemotherapy. Patients undergoing BCS re-
ceived radiation to the breast. The indication for loco-
regional radiation therapy (chest wall and regional nodal
basins) was based on the original staging before neo-
adjuvant chemotherapy. Hormone receptor-positive patients
received adjuvant endocrine treatment for at least 5 years
and HER2-positive patients received trastuzumab for
1 year.
FDG PET/CT
The FDG PET/CT scan was performed after conventional
imaging of the breast and the axilla. Patients were prepared
with a fasting period of 6 h and 10 mg Valium per os 10
min before FDG administration to avoid brown fat
activation. Blood glucose levels were required to be
<10 mmol/l. Patients received 180–240 MBq FDG intra-
venously. The interval between FDG administrations and
scanning was 60±10 min. A whole-body PET/CT scanner
(Gemini TF, Philips, Eindhoven, The Netherlands) was
used. FDG PET image acquisition was managed via
standardized acquisition procedures. Low-dose CT images
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were acquired for anatomical reference and attenuation
correction. First, a 2-mm high-resolution PET/CT was
performed of the thorax (including breasts and axilla) with
the patient in the prone position with hanging breasts and
3 min per bed position. Second, a whole-body PET/CT was
performed from the skull base to the groins, with 1.5 min
per bed position and standard image resolution. The
administered activity, time of FDG administration and
body weight on the day of scanning were recorded for
calculation of the tumour maximum standardized uptake
value (SUVmax).
Image interpretation
All FDG PET/CT scans were read in consensus by three
experienced readers. Visual assessments of locations, extent
and intensity of FDG uptake patterns were made. The FDG
uptake in the primary tumour and lymph node metastases
was analysed semi-quantitatively using the SUVmax and the
ratio of the SUVmax to the mean activity in an adjacent
sufficiently large area of normal surrounding tissue (tumour
to background ratio, TBR). Patients suitable for response
monitoring of the axilla were defined as having either an
SUVmax≥2.5 or a TBR ≥5 in the most intense lymph node
in the axilla.
Statistical analysis
The accuracy of FDG PET/CT to visualize lymph node
metastasis was evaluated by comparing the results of the
FDG PET/CT with the pathological results (tumour-positive
cytology or SNB results). The pathologist was blinded to
the FDG PET/CT results. The results were classified as
true-positive (TP), true-negative (TN), false-positive (FP)
and false-negative (FN). The evaluation of the results was
based on the sensitivity [TP/(TP+FN)], specificity [TN/
(TN+FP)] and overall accuracy [(TP+TN)/all cases].
The differences in SUVmax and TBRs between the
primary tumour and the axillary lymph node metastases
were calculated using the paired t test and the Wilcoxon
signed rank test. Differences in SUVmax between the
different tumour types were calculated using the one-way
analysis of variance (ANOVA) test.
Results
A total of 38 patients were included in this study. Patient
and tumour characteristics are outlined in Table 1. The
mean age of the patients was 49 years (range: 30–68). Most
patients had T2 (n=23) and ductal tumours (n=31) [18].
Primary tumours were oestrogen receptor (ER)-positive,
triple-negative (oestrogen receptor-, progesterone receptor-
and HER2-negative) and HER2-positive in 19, 17 and 11
patients, respectively. Twenty-nine patients had suspect
lymph nodes on ultrasound with tumour-positive FNA
cytology. In one patient only a suspect lymph node in the
internal mammary chain was palpable (cN2b) and one
patient had a positive subclavicular lymph node (cN3), both
confirmed by ultrasound-guided FNA cytology.
Positive FDG PET
FDG PET/CT showed pathological axillary lymph nodes in
30 patients (86%). In 27 of these 30 patients lymph node
metastasis had also been detected with ultrasound and
cytology. In one patient with a negative initial ultrasound
examination, FDG PET/CT was positive. Ultrasound was
subsequently repeated with FNA cytology, confirming a
tumour-positive axillary lymph node (Fig. 1). In two
patients with negative ultrasound and a positive FDG
PET/CT a SNB was done. In one patient the SNB revealed
macrometastases in three of four sentinel nodes. In the other
patient four lymph nodes were removed during the SNB
procedure and they were all tumour-negative. However,
follow-up FDG PET/CT images strongly suggested that the
suspect lymph nodes were not located in the area of the
excised sentinel nodes and had most likely been missed
(Fig. 2). We excluded this patient from our accuracy
analysis because of uncertainty about the initial lymph
node status.
Negative FDG PET
FDG PET/CT showed negative axillary lymph nodes in
eight patients. In one patient the FDG PET/CT was false-
negative because she had a proven axillary lymph node
metastasis by ultrasound-guided FNA cytology. Seven
patients had a negative ultrasound examination. Four of
these patients also had a tumour-negative SNB. In three
patients a SNB was not performed. After neoadjuvant
chemotherapy, none of these patients had axillary lymph
node metastases in the ALND specimen, but we excluded
them from our accuracy analysis because of uncertainty
about their initial lymph node status.
Feasibility of monitoring the axillary response
The results are summarized in Fig. 3. Excluding the cases
outlined above, 34 patients could be evaluated. The
sensitivity to visualize axillary lymph node metastasis was
97% [29/30, 95% confidence interval (CI): 0.83–0.99], the
specificity was 100% (4/4, 95% CI: 0.51–1.0) and the
overall accuracy was 97% (33/34). Ninety-three per cent
(29/31) of the patients had sufficient uptake in the lymph
Eur J Nucl Med Mol Imaging (2010) 37:1069–1076 1071nodes to qualify for subsequent response monitoring of the
axilla, an SUVmax≥2.5 or a TBR ≥5.
Extra-axillary lymph nodes
In 6 of 38 patients (16%) FDG PET/CT showed suspicious
uptake in extra-axillary lymph nodes that were not detected
by conventional imaging (Table 2). One patient had two
FDG PET-suspect lymph nodes, one intrapectoral and one
subclavicular, which were not detected by ultrasound
examination. In three patients FDG PET/CT indicated
additional lymph node metastases in the internal mammary
chain, a region that is not routinely assessed with
ultrasound. In one patient FDG PET/CT revealed an
unknown subclavicular lymph node metastasis and one
patient showed pathological uptake in the contralateral
axillary lymph nodes.
Differences between the primary tumour and the lymph
node metastasis
The primary tumour could be visualized in 37 of 38
patients. One patient presented with a palpable axillary
lymph node and an occult primary tumour that could not be
visualized on either FDG PET/CT or MRI. The mean
SUVmax of the primary tumours was 6.8 (range: 1.6–18.8,
95% CI: 5.1–8.0), with a mean TBR of 11.3 (range: 2.1–
36.0, 95% CI: 8.3–14.3).
Positive lymph nodes (axillary or extra-axillary) were
visualized in 31 of the 38 patients. The mean SUVmax of
Fig. 1 FDG PET scan of a
patient without suspect axillary
lymph nodes on initial ultra-
sound examination and a clear
tumour-positive lymph node on
FDG PET (arrow). Repeated
ultrasound examination with
cytology guided by FDG PET/
CT images revealed a tumour-
positive axillary lymph node
Table 1 Patients and tumour characteristics (total n=38)
Number %
Patient age, mean
(range)
49 years (30–68)
cT classification cT0 1 3
cT1 2 5
cT2 23 61
cT3 10 26
cT4 2 5
cN classification cN0 9 26
cN1 27 77
cN2b 1 3
cN3 1
Histology Ductal 31 82
Lobular 3 8
Mixed 1 2
NS 3 8
Receptor status ER-positive (HER2-negative) 19 51
Triple-negative (ER-/PR-/
HER2-negative)
71 9
HER2-positive 11 30
NS not specified, ER oestrogen receptor, PR progesterone receptor,
HER2 human epidermal growth factor receptor 2
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CI: 5.8–9.6). The mean TBR was 23.7 (range: 4.0–93.0,
95% CI: 15.2–32.1). Paired evaluation of the SUVmax of
the primary tumour and the related most active lymph node
in 30 patients with an active primary tumour and lymph
node metastasis showed no difference. Paired evaluation of
the TBR showed a significantly higher ratio (2.0) for the
lymph nodes (p=0.006), explained by higher background
uptake in the breast due to surrounding glandular tissue.
A considerable distinction in the SUVmax of both the
primary tumour and the lymph node metastases was
observed between the different subtypes of breast tumours.
In ER-positive, triple-negative and HER2-positive tumours
the mean SUVmax was 5.4 (95% CI: 3.7–7.1), 11.1 (95%
CI: 6.0–16.1) and 5.9 (95% CI: 3.3–8.6), respectively (p=
0.01). In the lymph node metastases the mean SUVmax of
ER-positive, triple-negative and HER2-positive tumours
was 6.6 (95% CI: 4.7–8.4), 11.6 (95% CI: 5.0–18.2) and
6.6 (95% CI: 2.7–10.6), respectively (p=0.07).
Discussion
This report describes the accuracy of FDG PET/CT to
visualize lymph node metastases in breast cancer before the
start of neoadjuvant chemotherapy. The overall accuracy in
this selected patient population was high: 97%. In 93% of
the patients the lymph nodes showed adequate uptake for
subsequent response monitoring of the axilla. Accurate
visualization of lymph node metastasis with sufficient
Fig. 2 FDG PET/CT scan of a patient with two FDG PET-positive
lymph nodes prior to neoadjuvant chemotherapy. Subsequently, the
patient had a negative SNB (a). After the administration of
chemotherapy (b) the lymph nodes show complete metabolic response
but are still clearly visible on the low-dose CT and were most likely
not removed at SNB. These findings suggest that the patient could
have a false-negative SNB procedure or a false-positive initial FDG
PET/CT
Fig. 3 FDG PET/CT versus conventional examination of the axilla,
showing the accuracy of FDG PET/CT to detect lymph node
metastases. The sensitivity to visualize axillary lymph node metastasis
was 97% (29/30, 95% CI: 0.83–0.99), the specificity was 100% (4/4,
95% CI: 0.51–1.0) and the overall accuracy was 97% (33/34). *This
patient most likely had a false-negative sentinel node and was
excluded from the analysis together with the three patients with
negative ultrasound-guided cytology and no SNB
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chemotherapy is the first requirement to monitor the
axillary response with FDG PET/CT imaging. With this
study we showed that it is reasonable to use FDG PET/CT
to assess the axillary response.
In our series the sensitivity of FDG PET/CT to visualize
lymph node metastases prior to neoadjuvant chemotherapy
was 97% (30/31). The sensitivity reported by others varies
widely (20–94%) [19]. Studies including patients with more
advanced primary tumours, similar to our population,
showed a sensitivity of 85% and higher [16, 20]. This high
sensitivity can be explained by the high a priori likelihood
of (voluminous) lymph node metastases. The sensitivity of
FDG PET/CT is lower in patients with early breast cancer
and a clinically negative axilla. In a prospective study
Veronesi et al. compared preoperative FDG PET imaging
with SNB and reported a sensitivity of only 37% [21]. The
authors demonstrated that FDG PET was unable to identify
micrometastases in the lymph nodes. The low sensitivity
and inability to detect micrometastases can be explained by
the relatively low spatial resolution of PET imaging, which
does not allow detection of the micrometastases found
using serial sectioning and immunohistochemistry at
pathological assessment of sentinel nodes. Other factors
that could influence the sensitivity of FDG PETare intrinsic
tumour characteristics like grade and type. There is
evidence that sensitivity of FDG PET is higher in certain
subgroups. Gil-Rendo et al. showed a sensitivity of 100%
to detect lymph node metastasis in a group of patients with
grade III malignancy and an SUVmax higher than 3.5 of the
primary tumour [22]. Moreover, Veronesi et al. used FDG
PET alone while integrated FDG PET/CT can provide both
anatomical and metabolic information, which in general
provides a better accuracy [23]. Several studies report the
superiority of FDG PET/CT compared with that of PET
alone [24–26].
In our series the specificity was 100%. This is confirmed
in other studies consistently reporting a high specificity
ranging from 85 to 100% [19]. These findings suggest that
an SNB procedure prior to the start of neoadjuvant
chemotherapy may not be necessary if FDG PET/CT shows
a positive axillary lymph node, at least in the absence of an
apparent inflammatory cause of lymph node activation such
as non-malignant mastitis. By omitting the SNB procedure
prior to neoadjuvant chemotherapy, the positive axillary
lymph node will remain in situ, which will create the
opportunity to monitor the axillary response in these
patients. In addition, the patient is spared an invasive
surgical diagnostic procedure.
Fuster et al. reported that FDG PET/CT is a valuable tool
to exclude unsuspected extra-axillary lymph node and
distant metastases in patients with large breast cancer
[27]. They showed that FDG PET/CT led to a change in
initial staging in 42% of patients, although it is critical to
note that they did not perform ultrasound assessment
combined with cytology of the axillary lymph nodes. In
our series, 16% of the patients had suspect extra-axillary
lymph node metastases by FGD PET/CT that were not
visualized by conventional imaging (ultrasound examina-
tion and SNB). A limitation of our study is that no biopsies
were taken of these suspect extra-axillary lymph nodes, but
the probability of nodal involvement is high based on the
reported specificity of FDG PET/CT.
FDG PET/CT may successfully monitor the response of
the primary tumour to neoadjuvant chemotherapy. Quanti-
tative FDG PET scans of primary breast cancers showed a
rapid and significant decrease in tumour glucose metabo-
lism after effective treatment was initiated, and the
reduction in metabolism antedated the decrease in tumour
size [11, 17]. Several studies investigated the accuracy of
FDG PET to monitor the response to neoadjuvant chemo-
therapy in breast cancer with reported sensitivity and
specificity of 84–100% and 74–94%, respectively [9, 10,
12–16]. These studies are difficult to compare since they
use different time points in the course of chemotherapy and
different cut-off points in the reduction of the SUV to
distinguish responders from non-responders. Overall, it
appears that the accuracy of FDG PET to monitor response
prediction is high early in the course of therapy. In our
study, FDG PET/CT is performed after one cycle of
chemotherapy to detect the early response to treatment.
However, complete metabolic responders are more likely to
occur after a longer course of systemic therapy. Therefore,
another scan is performed after the third cycle of chemo-
therapy. The published studies focused on response
monitoring of the primary tumour. No results have been
presented yet regarding the value of FDG PET to assess the
early response to neoadjuvant chemotherapy of axillary
lymph node metastases.
To monitor the early response of axillary lymph node
metastases using FDG PET/CT it is crucial to have a
sufficiently high baseline SUVmax or TBR at baseline. A
low baseline SUVmax can underestimate the subsequent
Table 2 Extra-axillary lymph node metastasis in 38 patients
Conventional imaging (US/
FNA positive)
FDG PET/CT
positive
Internal
mammary chain
14
Subclavicular 1 3
Intrapectoral – 1
Contralateral – 1
Total 2 (5%) 9 (24%)
US ultrasound, FNA fine-needle aspiration
1074 Eur J Nucl Med Mol Imaging (2010) 37:1069–1076tumour response [10]. McDermott et al. demonstrated that
only tumours with an initial TBR of greater than 5 showed
a difference between response categories [13]. Three
patients in our study had an SUVmax lower than 2.5 in the
axillary lymph nodes, and three patients had an SUVmax
lower than 2.5 in the primary tumour. The mean TBR was
90% higher in the axilla than in the primary tumour of the
breast, which might facilitate the evaluation of the tumour
response in the axillary lymph nodes compared to the
primary tumour. The baseline SUVmax is higher in triple-
negative tumours, which will make them more suitable for
response evaluation with FDG PET than ER-positive and
HER2-positive tumours.
Early axillary response monitoring may have several
clinical implications. It seems reasonable that the response
of axillary lymph node metastases to the chemotherapy is
highly indicative of the efficiency of chemotherapy,
particularly because the aim of chemotherapy is to
eliminate micrometastatic disease.
The ultimate goal is to adjust the treatment to the early
response of the axillary lymph node metastases. Further-
more, knowledge regarding the axillary response might
be used to tailor the surgical treatment of the axilla. FDG
PET/CT might select patients with a favourable axillary
response for more axillary-conserving therapies, like
axillary radiation therapy. Treatment is still required
since PET imaging cannot detect axillary microscopic
disease [21].
In conclusion, this study shows that lymph node
metastases can be visualized using FDG PET/CT with
good sensitivity and specificity. In addition, pathological
lymph nodes have a sufficiently high baseline SUVmax and
TBR at baseline to enable response monitoring, especially
in triple-negative tumours. Consequently, monitoring the
response of axillary lymph nodes with FDG PET/CT during
the early course of treatment may be feasible. Future
research will focus on establishing a cut-off point in the
therapy-induced change of SUVmax to discriminate nodal
responders from non-responders.
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